Skip to main content

Table 5 Adverse events

From: Improved home BP profile with dapagliflozin is associated with amelioration of albuminuria in Japanese patients with diabetic nephropathy: the Yokohama add-on inhibitory efficacy of dapagliflozin on albuminuria in Japanese patients with type 2 diabetes study (Y-AIDA study)

Event Grade 1 Grade 2 Grade 3
Special interest categories
 Hypoglycemia 6 (7.1%) 2 (2.4%) 0 (0.0%)
 Volume depletion 2 (2.4%) 0 (0.0%) 0 (0.0%)
 Urinary tract/genital infection 0 (0.0%) 1 (1.2%) 0 (0.0%)
 Cutaneous symptom 0 (0.0%) 0 (0.0%) 0 (0.0%)
Others
 Cold 2 (2.4%) 4 (4.7%) 0 (0.0%)
 Influenza 0 (0.0%) 3 (3.5%) 0 (0.0%)
 Pollenosis 1 (1.2%) 2 (2.4%) 0 (0.0%)
 Hypertension 0 (0.0%) 2 (2.4%) 0 (0.0%)
 Angina pectoris 0 (0.0%) 0 (0.0%) 1 (1.2%)
 Cataract 0 (0.0%) 0 (0.0%) 1 (1.2%)
 Retinal detachment 0 (0.0%) 0 (0.0%) 1 (1.2%)
 Vitreous surgery due to retinopathy 0 (0.0%) 0 (0.0%) 1 (1.2%)
 Cough variant asthma 0 (0.0%) 1 (1.2%) 0 (0.0%)
 Elevated LDL 0 (0.0%) 1 (1.2%) 0 (0.0%)
 Fever 0 (0.0%) 1 (1.2%) 0 (0.0%)
 Fracture 0 (0.0%) 1 (1.2%) 0 (0.0%)
 Hemorrhagic stool 0 (0.0%) 1 (1.2%) 0 (0.0%)
 Hordeolum 0 (0.0%) 1 (1.2%) 0 (0.0%)
 Prostatitis 0 (0.0%) 1 (1.2%) 0 (0.0%)
 Elevated CK 1 (1.2%) 0 (0.0%) 0 (0.0%)
 Nausea 1 (1.2%) 0 (0.0%) 0 (0.0%)
 Odontectomy 1 (1.2%) 0 (0.0%) 0 (0.0%)
 Pruritus 1 (1.2%) 0 (0.0%) 0 (0.0%)
 Thamuria 1 (1.2%) 0 (0.0%) 0 (0.0%)
 Wobbliness 1 (1.2%) 0 (0.0%) 0 (0.0%)
  1. Values are n (%)
  2. Evaluation of adverse events (AEs) was performed based on Common Terminology Criteria for Adverse Event version 4.0. Grade 1: mild (no need for therapeutic intervention); Grade 2: moderate (needs therapeutic intervention in outpatient clinic); Grade 3: severe (needs therapeutic intervention by admission); Grade 4: life threatening, or places the participant, in the view of the investigator, at immediate risk of death from the experience as it occurred; Grade 5: death. AEs of Grade 4 or 5 were not reported
  3. LDL low-density lipoprotein cholesterol, CK creatine kinase